dc.relation.reference | 1. 行政院衛生署.衛生統計、生命統計.台北.衛生署.2002.
2. 葛應欽、李建宏等.不吸菸婦女肺癌研究.生命科學簡迅第十三卷第四期p12-15.
3. 行政院衛生署.台灣地區癌症登記調查報告.台北.衛生署.民國89年.
4. Yang SP, Luh KT, Kuo SH, et al. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration-A 30-year consecutive study. Jpn J Clin Oncol 14(1): 7-19,1984.
5. 廖國盟.博士論文.台灣地區女性肺腺癌分子流行病學研究, 2002.
6. Lin CC. A study of lung cancer in Taiwan. Jpn J Chest Dis, 7:1593-1603.
7. Luh KT, Kuo SW, Lin CC, et al. Primary lung cancer in Taiwan. J Formosan Med Assoc, 73:129-146,1974.
8. Lee LT, Lee WC, Lin RS, et al. Age-period-cohort analysis of lung cancer mortality in Taiwan, 1966-1990. Anticancer Res, 14:673-76,1994.
9. 陸坤泰, 張登斌. 台灣的肺癌. 台灣醫誌, 91卷附冊1: s1-s7,1992.
10. Tay SC, Tsai SF, Lee SS, et al. Lung cancer in Taiwan. Natl Public Health Assoc (ROC), 8(3): 189-201, 1998.
11. 蕭光明. 台灣地區肺癌之流行病學特徵.臨床醫學, 29: 347-52,1992.
12. Beattle CW, Hansen NW, Thomas PA. Steroid receptors in human lung cancer. Cancer Res: 45, 4206-14, 1985.
13. Cagle PT, Mody DR, Schwartz MR. Estrogen and Progesterone receptor in bronchogenic carcinoma. Cancer Res: 50, 6632-35, 1990.
14. Ollayos CW, Riodon GP, Rubin JM. Estrogen receptor detection in paraffin sections of adenocarcinoma of colon, pancreas, and lung. Arch Patho Lab Med: 118, 630-32, 1994.
15. Canver CC, Memoli VA, Vanderveer PL, et al. Sex-Hormone receptors in non-small cell lung cancer in human beings. J Thorac Cardiovas Surg: 108, 153-57, 1994.
16. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in non-small cell lung cancer: immonohistochemical study. Anticancer Res: 16, 3803-06, 1996.
17. Kaiser U, Hoffman J, Schilii B, et al. Steroid-hormone receptors in cell lines amd tomor biopsies of human lung cancer. Int J Cancer: 67, 357-64, 1996.
18. Gao YT, Blot WJ, Wei Z, et al. Lung cancer among Chinese woman. Int J Cancer, 40: 604-09, 1987.
19. Taioli E, Wynder EL. Endocrine factors and adenocarcinoma of the lung in woman. J Natl Cancer Inst, 86: 869-70, 1994.
20. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst, 93(8): 605-18, 2001.
21. Sellers TA, Potter JD, Folsom AR. Association of incident lung cancer with family history of female reproductive cancers: The Iowa women’s health study. Genet Epidemiol: 8, 199-208, 1991.
22. Noronha RFX, Goodal CM. Enhancement by testosterone of dimethylnitrosamine carcinogenesis in lung, liver, anf kidney of inbed NZR/Gd female rats. Carcinogenesis: 4, 613-16, 1983.
23. Risch HA, Howe GR, Jain M. Are female smoker at high risk of lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol, 138: 281-293, 1993.
24. Brian E, Bruce P, Ronald K. Hormones, Genes, And Cancer. Oxford, 2003.
25. Gregory JB, Gretchen JD. Isolation of DNA from biological specimens without extraction with phenol. Clinical chemistry 31: 164-5, 1985.
26. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Necleic Acids Research 16: 1215, 1988.
27. Haiman CA, Hankison SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87: 204-10, 2000.
28. Felgelson HS, Shames LS, Pike MC, et al. Cytochrome p450c17α gene(CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res, 58: 585-87, 1998.
29. Felgelson HS, Coetzz GA, Kolonel LN, et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res, 57: 1063-65, 1997.
30. Dunning AM, Pharoah PDP, Foster NA, et al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer, 77: 2045-47, 1998.
31. Brodie A, Lu Q, Nakumura J. Aromatase in the normal breast and breast cancer. J Steroid Biochem Mol Biol, 61: 281-86, 1997.
32. Kristensen VN, Anderson TI, Lindblom A, et al. A rare CYP19(aromatase) variat may increase the risk of breast cancer. Pharmacogenet, 8:43-8. 1998.
33. Haiman CA, Hankinson SE, Speizer FE, Hunter DJ. A tetranucleotide repeat polymorphism in CYP19 and breast cancer. Proc Am Assoc Cancer Res, 40: 194, 1999.
34. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann. N. Y. Acad. Sci., 768: 91-100, 1995.
35. Aswegen CH, Purdy RH, Wittliff JL. Binding of 2-hydroxyestradiol and 4-hydroxyestrodiol to estrogen receptor human breast cancers. J Steroid Biochem, 32: 485-92, 1989.
36. Taioli E, Trachman J, Chen X, et al. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in Africa-American women. Cancer Res, 55: 3757-8, 1995.
37. Ambrosone CB, Freudenheim JL, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphism and postmenopausal breast cancer risk. Cancer Res, 55: 3483-5, 1995.
38. Ishibe N, Hankinson SE, Coldtiz GA, et al. Cigarette smoking, cytochrome P4501A1 polymophism, and breast cancer risk in the Nurses’ Health Study. Cancer Res, 58: 667-71, 1998.
39. Huang CS, Shen CY, Chanf KJ, et al. Cytochrome P4501A1 polymorphism as a susceptibility factor for breast cancer in postmenopausal Chinese women in Taiwan. Br J Cancer, 80: 1838-43, 1999.
40. Yasuo M, Kyoko I, Noriko I, et al. Breast Cancer Risk Associated With Polymorphism in CYP19 in JAPANESE Women. Int J Cancer, 89: 325-8, 2000.
41. Kazuhiro S, Haruki N, Hiroshi M, et al. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer, 98(7): 1411-16, 2003.
42. Omiecinski CJ, Redlich CA, Costa P. Induction and development expression of cytochrome P4501A1 messenger RNA in rat and human tissue: detection of the polymerase chain reaction. Cancer Res, 50: 4315-21, 1990.
43. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetic high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett, 263: 131-33, 1990.
44. Hirvonen A, Husgafvel-Pursiainen K, Karajalainen A, et al. Point-mutation MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prevention, 1: 485-89, 1992.
45. Tefre T, Ryberg D, Huagen A, et al. Human CYP1A1 gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Phamarcogenetics, 1: 20-25, 1991.
46. Shield PG, Sugimura H, Caporaso NE, et al. Polycyclic aromatic hydrocarbon DNA adducts and the CYP1A1 restriction fragment length polymorphism. Environ Hlth Perspect, 98: 191-4, 1992.
47. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5’ flanking region of the human CYP1A2 gene effect on the CYP1A2 inducibility in humans. J Biochem, 125: 803-8, 1999.
48. Bailey LR, Roodi N, Dupont WD, et al. Association of Cytochrome P4501B1 polymorphism with steroid receptor status in breast cancer. Cancer Res, 58: 5038-41, 1998.
49. Masahiro S, Yuichiro T, Masanori K, et al. CYP1B1 gene polymorphism have higher risk for endometrial cancer, and positive correlations with estrogen receptor α and estrogen receptor β expressions. Cancer Res, 63: 3913-18, 2003.
50. Junko W, Tsutomu S, Elizabeth MJ, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics, 10: 25-33, 2000.
51. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of COMT and the risk of breast cancer. Cancer Res, 57: 5493-97, 1997.
52. Thompson PA, Shield PG, Freudenheim JL, et al. Genetic polymorphism in the COMT, menopausal status, and breast cancer risk. Cancer Res, 58: 2107-10,1998.
53. Fugua SA, Chamness GC, McGuire WL. Estrogen receptor mutations in breast cancer. J Cell Biochem, 51: 135-9,1993.
54. Su JM, Hsu HK, Chang H, et al. Expression of estrogen and progesterone receptors in nonsmall-cell lung cancer: Immunohistochemical study. Anticancer Res, 16: 3803-06, 1996.
55. Ollayos LT, Riordan GP, Rushin CD. Estrogen receptor detection in paraffin sections of adenocarcinoma of colon, pancreas and lung. Arch Patho Lab Med, 118: 630-2, 1994.
56. Cagle PT, Mody DR, Schwartz MR. Estrogen and progesterone receptors in bronchogenic carcinoma. Caner Res, 50: 6632-5, 1990.
57. Kuiper GC, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor α and β. Endocrinology, 138: 863-70, 1997.
58. Steen M, Kjersti J, Gisle B, et al. Expression of estrogen cereptorsα and β in human lung tissue and cell lines. Lung Cancer, 37: 153-9,2002.
59. Roodi N, Bailey LR, Kao WY, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cnacer. J Natl Cancer Inst, 87: 446-451, 1995.
60. Southy MC, Battern LE, McCredie MR, et al. Estrogen receptor polymorphism at codon 325 and risk of breast cancer in women before age forty. J Natl Cancer Inst, 90: 532-36, 1998.
61. Cai QY, Shu XO, Dai Q, et al. Genetic polymorphisms of estrogen receptor-α gene and risk of breast cancer: Results from the Shanghai Breast Cancer Study. Cancer Epidemio Biomark Prev, in Press, 2003.
62. An J, Ribeiro P, Webb JA, et al. Leitman, estrodiol repression of tumour necrosis factor α transcription requires estrogen receptor activation function-2 and is enhanced by coacticators, Proc. Natl Acad Sci. USA, 96: 15161-15166, 1999.
63. Barbara A, Janez P, Radovan K, et al. No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis. J Steroid Biochem Mol Biology, 81: 147-52, 2002.
64. Levesque E, Beaulieu M, Green MD, et al. Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltansferase encoded by a polymorphic gene. Pharmarcogenetics, 7(4): 317-25, 1997.
65. Tine H, Boris Z. Prostate cancer and polymorphism D85Y in gene for dihydrotestpsterone degrading enzyme: UGT2B15: frequency of DD homozygotes increase with Gleason score. The Prostate, 59: 436-39, 2004.
66. Stewart L, Susan N, Jason P, et al. An allele-specific polymerase chain reaction method for determination of the D85Y polymorphism in the human UGT2B15 gene in a case-control study of prostate cancer. Ann Surgical Oncol, 7(10): 777-82, 2000.
67. Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer, 44: 833-39, 1989.
68. Huang CS, Chern HD, Chang KJ, et al. Breast cancer risk associated with genotype polymorphism of the estrogen-matabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility. Cancer Res, 59: 4870-75, 1999.
69. Carey AH, Waterworth D, Patel K, et al. Polycyclic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet, 3: 1873-76, 1994.
70. Haiman CA, Hankinson SE, Speigelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res, 59: 1015-20,1999.
71. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis, 15: 2961, 1994.
72. Kiyohaya C, Hirohaha T, Inutsuka S,. The relationship between aryl hydrocarbon hydroxylase and polymorphism of the CYP1A1 gene. Jpn J Cancer Res, 87: 18, 1996.
73. Zhang ZY, Fasco MJ, Huang L, et al. Characterization of purified human recombinant Cytochrome P4501A1-Ile462 and Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res, 56: 3926, 1996.
74. Peterson DD, Mickinney CE, Ikeya K, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet, 48: 720-725, 1991.
75. Shield PG, Bowman ED, Harrington AM, et al. A polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility gene. Cancer Res, 53: 3486, 1993.
76. Houlston RS. CYP1A1 polymorphism and lung cancer risk: a meta-analysis. Pharmacogenetics, 10(2): 105-14, 2000.
77. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis, 19: 1-27, 1998.
78. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Ann Rev Pharmocol Toxicol, 36: 203-232, 1996.
79. Hill SM, Fuqua SA, Chamness GC, et al. Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism. Cancer Res, 49: 145-8, 1989.
80. Stabile LP, Siegfried JM. Estrogen receptor pathways in lung cancer. Curr Oncol Rep, 6(4): 259-67, 2004.
81. Kobayashi S, Inoue S, Hosoi T, et al. Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res, 11: 306-11, 1996.
82. Kurabayashi T, Tomita M, Matsushita H, et al. Association of vitamin D and estrogen receptor gene polymorphism woth the effect of hormone replacement therapy on bone mineral density in Japanese women. Am J Obstet Gynecol, 180: 1115-20, 1999.
83. Nakachi K, Imai K, Hayashi S, et al. Polymorphism of the CYP1A1 and Glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in Japanese polupation. Cancer Res, 53: 2994-99, 1993. | zh_TW |